S. 1040Introduced
Drug Competition Enhancement Act
Prohibits drug manufacturers from using product hopping to block generic or biosimilar competition and lets the FTC enforce that ban
Plain-English overview
What this bill does
Prohibits drug manufacturers from using product hopping to block generic or biosimilar competition and lets the FTC enforce that ban
Key points
- Establish rebuttable presumptions
- Prohibit product hopping
- Authorize FTC enforcement
Current status
Where it stands
Status
Introduced
Latest action
2025-04-10 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
Related context
Topics and policy areas
undefinedAdministrative remediesCivil actions and liabilityCompetition and antitrustConsumer affairsDrug safety, medical device, and laboratory regulationFederal Trade Commission (FTC)Health